[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fL2vutv5WS6-hjdFLHsTjCCunvGEPJ1ThEtI19r0eKzE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"University Hospital, Essen",[4],111,false,28,5,112964,87,[13,16,19,22,24,27,29,31],{"name":14,"count":15},"Heart Failure",9,{"name":17,"count":18},"Peripheral Arterial Disease",7,{"name":20,"count":21},"Myocardial Infarction",4,{"name":23,"count":21},"Coronary Artery Disease",{"name":25,"count":26},"Cardiac Amyloidosis",3,{"name":28,"count":26},"Coronary Heart Disease",{"name":30,"count":26},"Lung Cancer",{"name":32,"count":26},"Aging",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05087784","AlloLife - Life After Transplantation","2025-12","Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06784791","Preoperative Amivantamab or Amivantamab and Carboplatin\u002FPemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","2027-07-31","Amivantamab Intravenous",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04309409","Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma","2027-09","Nivolumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07546669","Efficacy of Zoster Vaccination in Glioblastoma Patients","2029-12-31","Additional vaccination against shingles",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,87,129,153,171,193,220,238,264,282,308,335,353,388,412,430,448,466,484,502,520,538,563,591,616,643,661,687,705,731,756,783,801,825,851,869,887,913],{"intervention":53,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":74,"NA":85},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":67},[],{"trials":75,"activeCount":63,"soonestReadout":52},[76],{"nctId":50,"briefTitle":51,"status":77,"phases":78,"primaryCompletion":52,"completion":79,"start":80,"enrollment":81,"conditions":82,"interventions":84},"NOT_YET_RECRUITING",[59],"2030-12-31","2027-01-02",230,[83],"Glioblastoma (GBM)",[53],{"trials":86,"activeCount":67},[],{"intervention":48,"totalTrials":88,"cells":89},2,{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":114,"PHASE4":125,"NA":127},{"trials":91,"activeCount":67},[],{"trials":93,"activeCount":67},[],{"trials":95,"activeCount":67},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"NCT04062656","Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","UNKNOWN",[57],"2024-03","2025-06-01","2019-09-26",21,[106,107],"Gastric Cancer","Adenocarcinoma of the Esophagogastric Junction",[48,109,110,111,112,113],"relatlimab","Oxaliplatin","Docetaxel","5-Fluorouracil","Folic acid",{"trials":115,"activeCount":63,"soonestReadout":47},[116],{"nctId":45,"briefTitle":46,"status":117,"phases":118,"primaryCompletion":47,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"ACTIVE_NOT_RECRUITING",[58],"2028-01","2020-07-01",374,[123],"Malignant Melanoma Stage II",[48],{"trials":126,"activeCount":67},[],{"trials":128,"activeCount":67},[],{"intervention":43,"totalTrials":63,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":132,"activeCount":67},[],{"trials":134,"activeCount":67},[],{"trials":136,"activeCount":63,"soonestReadout":42},[137],{"nctId":40,"briefTitle":41,"status":138,"phases":139,"primaryCompletion":42,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"RECRUITING",[57],"2027-12-31","2024-11-06",20,[144],"Lung Cancer (NSCLC)",[43,146],"Carboplatin\u002FPemetrexed",{"trials":148,"activeCount":67},[],{"trials":150,"activeCount":67},[],{"trials":152,"activeCount":67},[],{"intervention":146,"totalTrials":63,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":156,"activeCount":67},[],{"trials":158,"activeCount":67},[],{"trials":160,"activeCount":63,"soonestReadout":42},[161],{"nctId":40,"briefTitle":41,"status":138,"phases":162,"primaryCompletion":42,"completion":140,"start":141,"enrollment":142,"conditions":163,"interventions":164},[57],[144],[43,146],{"trials":166,"activeCount":67},[],{"trials":168,"activeCount":67},[],{"trials":170,"activeCount":67},[],{"intervention":38,"totalTrials":63,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":183},{"trials":174,"activeCount":67},[],{"trials":176,"activeCount":67},[],{"trials":178,"activeCount":67},[],{"trials":180,"activeCount":67},[],{"trials":182,"activeCount":67},[],{"trials":184,"activeCount":63,"soonestReadout":37},[185],{"nctId":35,"briefTitle":36,"status":77,"phases":186,"primaryCompletion":37,"completion":187,"start":101,"enrollment":188,"conditions":189,"interventions":192},[60],"2026-06",192,[190,191],"Survivorship","Stem Cell Transplant Complications",[38],{"intervention":194,"totalTrials":63,"cells":195},"Prednisone",{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":216,"NA":218},{"trials":197,"activeCount":67},[],{"trials":199,"activeCount":67},[],{"trials":201,"activeCount":67},[],{"trials":203,"activeCount":67},[204],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT02334813","Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia","COMPLETED",[58],"2015-01","2002-07",26,[213],"Purpura, Thrombocytopenic, Idiopathic",[194,215],"Dexamethasone",{"trials":217,"activeCount":67},[],{"trials":219,"activeCount":67},[],{"intervention":215,"totalTrials":63,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":67},[],{"trials":225,"activeCount":67},[],{"trials":227,"activeCount":67},[],{"trials":229,"activeCount":67},[230],{"nctId":205,"briefTitle":206,"status":207,"phases":231,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":232,"interventions":233},[58],[213],[194,215],{"trials":235,"activeCount":67},[],{"trials":237,"activeCount":67},[],{"intervention":239,"totalTrials":63,"cells":240},"(R-)CHOP protocol",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":260,"NA":262},{"trials":242,"activeCount":67},[],{"trials":244,"activeCount":67},[],{"trials":246,"activeCount":67},[],{"trials":248,"activeCount":67},[249],{"nctId":250,"briefTitle":251,"status":207,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":258},"NCT00554164","Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas",[58],"2017-03","2007-11",1073,[257],"Lymphoma, High-grade",[239,259,239,239],"B-ALL protocol",{"trials":261,"activeCount":67},[],{"trials":263,"activeCount":67},[],{"intervention":259,"totalTrials":63,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":278,"NA":280},{"trials":267,"activeCount":67},[],{"trials":269,"activeCount":67},[],{"trials":271,"activeCount":67},[],{"trials":273,"activeCount":67},[274],{"nctId":250,"briefTitle":251,"status":207,"phases":275,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":276,"interventions":277},[58],[257],[239,259,239,239],{"trials":279,"activeCount":67},[],{"trials":281,"activeCount":67},[],{"intervention":283,"totalTrials":63,"cells":284},"isoflurane+sufentanil anesthesia",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":304,"NA":306},{"trials":286,"activeCount":67},[],{"trials":288,"activeCount":67},[],{"trials":290,"activeCount":67},[],{"trials":292,"activeCount":67},[293],{"nctId":294,"briefTitle":295,"status":207,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT01406678","Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest",[57,58],"2018-03","2020-04","2008-07",1204,[302],"Myocardial Injury",[283],{"trials":305,"activeCount":67},[],{"trials":307,"activeCount":67},[],{"intervention":309,"totalTrials":63,"cells":310},"Envarsus®",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":331,"NA":333},{"trials":312,"activeCount":67},[],{"trials":314,"activeCount":67},[],{"trials":316,"activeCount":67},[],{"trials":318,"activeCount":67},[319],{"nctId":320,"briefTitle":321,"status":99,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},"NCT06057545","Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation",[58],"2024-12","2025-03","2023-04-25",30,[328],"Pediatric Kidney Disease",[309,330],"Prograf",{"trials":332,"activeCount":67},[],{"trials":334,"activeCount":67},[],{"intervention":330,"totalTrials":63,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":349,"NA":351},{"trials":338,"activeCount":67},[],{"trials":340,"activeCount":67},[],{"trials":342,"activeCount":67},[],{"trials":344,"activeCount":67},[345],{"nctId":320,"briefTitle":321,"status":99,"phases":346,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":347,"interventions":348},[58],[328],[309,330],{"trials":350,"activeCount":67},[],{"trials":352,"activeCount":67},[],{"intervention":354,"totalTrials":88,"cells":355},"Atezolizumab",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":357,"activeCount":67},[],{"trials":359,"activeCount":67},[],{"trials":361,"activeCount":67},[362,373],{"nctId":363,"briefTitle":364,"status":207,"phases":365,"primaryCompletion":101,"completion":101,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT02902029","Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",[57],"2016-11",186,[369],"Malignant Melanoma",[371,372,354],"Vemurafenib","Cobimetinib",{"nctId":374,"briefTitle":375,"status":207,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":142,"conditions":379,"interventions":381},"NCT04939480","Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN",[57],"2024-03-14","2021-10-06",[380],"Squamous Cell Carcinoma of Head and Neck",[354],{"trials":383,"activeCount":67},[],{"trials":385,"activeCount":67},[],{"trials":387,"activeCount":67},[],{"intervention":389,"totalTrials":63,"cells":390},"mFOLFOX6, Atezolizumab and Bevacizumab",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":392,"activeCount":67},[],{"trials":394,"activeCount":67},[],{"trials":396,"activeCount":67},[397],{"nctId":398,"briefTitle":399,"status":207,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":142,"conditions":403,"interventions":405},"NCT05052099","Phase Ib\u002FII Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer",[56,57],"2024-09-18","2021-10-22",[404],"Biliary Tract Cancer",[389],{"trials":407,"activeCount":67},[],{"trials":409,"activeCount":67},[],{"trials":411,"activeCount":67},[],{"intervention":109,"totalTrials":63,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":424,"PHASE4":426,"NA":428},{"trials":415,"activeCount":67},[],{"trials":417,"activeCount":67},[],{"trials":419,"activeCount":67},[420],{"nctId":97,"briefTitle":98,"status":99,"phases":421,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":422,"interventions":423},[57],[106,107],[48,109,110,111,112,113],{"trials":425,"activeCount":67},[],{"trials":427,"activeCount":67},[],{"trials":429,"activeCount":67},[],{"intervention":110,"totalTrials":63,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":442,"PHASE4":444,"NA":446},{"trials":433,"activeCount":67},[],{"trials":435,"activeCount":67},[],{"trials":437,"activeCount":67},[438],{"nctId":97,"briefTitle":98,"status":99,"phases":439,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":440,"interventions":441},[57],[106,107],[48,109,110,111,112,113],{"trials":443,"activeCount":67},[],{"trials":445,"activeCount":67},[],{"trials":447,"activeCount":67},[],{"intervention":111,"totalTrials":63,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":451,"activeCount":67},[],{"trials":453,"activeCount":67},[],{"trials":455,"activeCount":67},[456],{"nctId":97,"briefTitle":98,"status":99,"phases":457,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":458,"interventions":459},[57],[106,107],[48,109,110,111,112,113],{"trials":461,"activeCount":67},[],{"trials":463,"activeCount":67},[],{"trials":465,"activeCount":67},[],{"intervention":112,"totalTrials":63,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":469,"activeCount":67},[],{"trials":471,"activeCount":67},[],{"trials":473,"activeCount":67},[474],{"nctId":97,"briefTitle":98,"status":99,"phases":475,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":476,"interventions":477},[57],[106,107],[48,109,110,111,112,113],{"trials":479,"activeCount":67},[],{"trials":481,"activeCount":67},[],{"trials":483,"activeCount":67},[],{"intervention":113,"totalTrials":63,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":487,"activeCount":67},[],{"trials":489,"activeCount":67},[],{"trials":491,"activeCount":67},[492],{"nctId":97,"briefTitle":98,"status":99,"phases":493,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":494,"interventions":495},[57],[106,107],[48,109,110,111,112,113],{"trials":497,"activeCount":67},[],{"trials":499,"activeCount":67},[],{"trials":501,"activeCount":67},[],{"intervention":371,"totalTrials":63,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":505,"activeCount":67},[],{"trials":507,"activeCount":67},[],{"trials":509,"activeCount":67},[510],{"nctId":363,"briefTitle":364,"status":207,"phases":511,"primaryCompletion":101,"completion":101,"start":366,"enrollment":367,"conditions":512,"interventions":513},[57],[369],[371,372,354],{"trials":515,"activeCount":67},[],{"trials":517,"activeCount":67},[],{"trials":519,"activeCount":67},[],{"intervention":372,"totalTrials":63,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":532,"PHASE4":534,"NA":536},{"trials":523,"activeCount":67},[],{"trials":525,"activeCount":67},[],{"trials":527,"activeCount":67},[528],{"nctId":363,"briefTitle":364,"status":207,"phases":529,"primaryCompletion":101,"completion":101,"start":366,"enrollment":367,"conditions":530,"interventions":531},[57],[369],[371,372,354],{"trials":533,"activeCount":67},[],{"trials":535,"activeCount":67},[],{"trials":537,"activeCount":67},[],{"intervention":539,"totalTrials":63,"cells":540},"Lenalidomide",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":542,"activeCount":67},[],{"trials":544,"activeCount":67},[],{"trials":546,"activeCount":67},[547],{"nctId":548,"briefTitle":549,"status":207,"phases":550,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT01788189","Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas",[56,57],"2020-02-20","2013-01",37,[555],"B-cell Lymphoma",[539],{"trials":558,"activeCount":67},[],{"trials":560,"activeCount":67},[],{"trials":562,"activeCount":67},[],{"intervention":564,"totalTrials":63,"cells":565},"Osimertinib",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":567,"activeCount":67},[],{"trials":569,"activeCount":67},[],{"trials":571,"activeCount":67},[572],{"nctId":573,"briefTitle":574,"status":207,"phases":575,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":584},"NCT03810066","Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)",[57],"2021-12-31","2022-09-30","2019-06-03",16,[581,582,583],"NSCLC","EGFR T790M","FDG-PET",[564],{"trials":586,"activeCount":67},[],{"trials":588,"activeCount":67},[],{"trials":590,"activeCount":67},[],{"intervention":592,"totalTrials":63,"cells":593},"Ipilimumab",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":610,"PHASE4":612,"NA":614},{"trials":595,"activeCount":67},[],{"trials":597,"activeCount":67},[],{"trials":599,"activeCount":67},[600],{"nctId":601,"briefTitle":602,"status":603,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":63,"conditions":607,"interventions":609},"NCT06388369","Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer","TERMINATED",[56,57],"2026-03-09","2025-08-25",[608],"Very High Risk Prostate Carcinoma",[592],{"trials":611,"activeCount":67},[],{"trials":613,"activeCount":67},[],{"trials":615,"activeCount":67},[],{"intervention":617,"totalTrials":63,"cells":618},"BKM120",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":620,"activeCount":67},[],{"trials":622,"activeCount":67},[],{"trials":624,"activeCount":67},[625],{"nctId":626,"briefTitle":627,"status":207,"phases":628,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT02404844","Trial of BKM120\u002FTamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer",[57],"2017-09-19","2017-10-19","2014-12",48,[634],"Breast Cancer",[617,636],"Tamoxifen",{"trials":638,"activeCount":67},[],{"trials":640,"activeCount":67},[],{"trials":642,"activeCount":67},[],{"intervention":636,"totalTrials":63,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":646,"activeCount":67},[],{"trials":648,"activeCount":67},[],{"trials":650,"activeCount":67},[651],{"nctId":626,"briefTitle":627,"status":207,"phases":652,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":653,"interventions":654},[57],[634],[617,636],{"trials":656,"activeCount":67},[],{"trials":658,"activeCount":67},[],{"trials":660,"activeCount":67},[],{"intervention":662,"totalTrials":63,"cells":663},"Trametinib 2 MG [Mekinist]",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":665,"activeCount":67},[],{"trials":667,"activeCount":67},[],{"trials":669,"activeCount":67},[670],{"nctId":671,"briefTitle":672,"status":99,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT04619316","Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition",[57],"2024-12-31","2018-02-05",70,[678],"Metastatic Thyroid Cancer",[662,680],"Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]",{"trials":682,"activeCount":67},[],{"trials":684,"activeCount":67},[],{"trials":686,"activeCount":67},[],{"intervention":680,"totalTrials":63,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":690,"activeCount":67},[],{"trials":692,"activeCount":67},[],{"trials":694,"activeCount":67},[695],{"nctId":671,"briefTitle":672,"status":99,"phases":696,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":697,"interventions":698},[57],[678],[662,680],{"trials":700,"activeCount":67},[],{"trials":702,"activeCount":67},[],{"trials":704,"activeCount":67},[],{"intervention":706,"totalTrials":63,"cells":707},"Eculizumab",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":709,"activeCount":67},[],{"trials":711,"activeCount":67},[],{"trials":713,"activeCount":67},[714],{"nctId":715,"briefTitle":716,"status":207,"phases":717,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT01303952","Therapy of Chronic Cold Agglutinin Disease With Eculizumab",[57],"2014-09","2015-06","2011-01",13,[723],"Cold Agglutinin Disease",[706],{"trials":726,"activeCount":67},[],{"trials":728,"activeCount":67},[],{"trials":730,"activeCount":67},[],{"intervention":732,"totalTrials":63,"cells":733},"Durvalumab",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":735,"activeCount":67},[],{"trials":737,"activeCount":67},[],{"trials":739,"activeCount":67},[740],{"nctId":741,"briefTitle":742,"status":99,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":749},"NCT04202809","Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus\u002FMinus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.",[57],"2025-04","2020-01-13",90,[748],"NSCLC, Stage III",[732],{"trials":751,"activeCount":67},[],{"trials":753,"activeCount":67},[],{"trials":755,"activeCount":67},[],{"intervention":757,"totalTrials":63,"cells":758},"Nivolumab 10 MG\u002FML Intravenous Solution",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":760,"activeCount":67},[],{"trials":762,"activeCount":67},[],{"trials":764,"activeCount":67},[765],{"nctId":766,"briefTitle":767,"status":99,"phases":768,"primaryCompletion":324,"completion":769,"start":770,"enrollment":746,"conditions":771,"interventions":775},"NCT04205552","Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients",[57],"2025-06","2020-03-04",[772,773,774],"NSCLC Stage II","NSCLC, Stage IIIA","NSCLC, Stage I",[757,776],"Relatlimab 10 MG\u002FML Intravenous Solution",{"trials":778,"activeCount":67},[],{"trials":780,"activeCount":67},[],{"trials":782,"activeCount":67},[],{"intervention":776,"totalTrials":63,"cells":784},{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":786,"activeCount":67},[],{"trials":788,"activeCount":67},[],{"trials":790,"activeCount":67},[791],{"nctId":766,"briefTitle":767,"status":99,"phases":792,"primaryCompletion":324,"completion":769,"start":770,"enrollment":746,"conditions":793,"interventions":794},[57],[772,773,774],[757,776],{"trials":796,"activeCount":67},[],{"trials":798,"activeCount":67},[],{"trials":800,"activeCount":67},[],{"intervention":802,"totalTrials":63,"cells":803},"LC-RT-PCR and NGS",{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":805,"activeCount":67},[],{"trials":807,"activeCount":67},[],{"trials":809,"activeCount":67},[],{"trials":811,"activeCount":67},[],{"trials":813,"activeCount":67},[],{"trials":815,"activeCount":67},[816],{"nctId":817,"briefTitle":818,"status":207,"phases":819,"primaryCompletion":820,"completion":366,"start":821,"enrollment":632,"conditions":822,"interventions":824},"NCT02975752","EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA",[],"2016-06","2015-03",[823],"Lung Adenocarcinoma Metastatic",[802],{"intervention":826,"totalTrials":63,"cells":827},"Dabigatran Etexilate Oral Capsule [Pradaxa]",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":829,"activeCount":67},[],{"trials":831,"activeCount":67},[],{"trials":833,"activeCount":67},[],{"trials":835,"activeCount":67},[],{"trials":837,"activeCount":67},[],{"trials":839,"activeCount":67},[840],{"nctId":841,"briefTitle":842,"status":207,"phases":843,"primaryCompletion":576,"completion":576,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT04062097","Registration of Idarucizumab for Patients with IntraCranial Hemorrhage",[],"2019-09-19",104,[847],"Intracranial Hemorrhage",[826,849,850],"Idarucizumab 2.5 GM\u002F50 ML Intravenous Solution [PRAXBIND]","Vitamin K antagonist",{"intervention":849,"totalTrials":63,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":67},[],{"trials":856,"activeCount":67},[],{"trials":858,"activeCount":67},[],{"trials":860,"activeCount":67},[],{"trials":862,"activeCount":67},[],{"trials":864,"activeCount":67},[865],{"nctId":841,"briefTitle":842,"status":207,"phases":866,"primaryCompletion":576,"completion":576,"start":844,"enrollment":845,"conditions":867,"interventions":868},[],[847],[826,849,850],{"intervention":850,"totalTrials":63,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":872,"activeCount":67},[],{"trials":874,"activeCount":67},[],{"trials":876,"activeCount":67},[],{"trials":878,"activeCount":67},[],{"trials":880,"activeCount":67},[],{"trials":882,"activeCount":67},[883],{"nctId":841,"briefTitle":842,"status":207,"phases":884,"primaryCompletion":576,"completion":576,"start":844,"enrollment":845,"conditions":885,"interventions":886},[],[847],[826,849,850],{"intervention":888,"totalTrials":63,"cells":889},"Heart failure medication",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":67},[],{"trials":893,"activeCount":67},[],{"trials":895,"activeCount":67},[],{"trials":897,"activeCount":67},[],{"trials":899,"activeCount":67},[],{"trials":901,"activeCount":67},[902],{"nctId":903,"briefTitle":904,"status":207,"phases":905,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT05636774","Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial",[60],"2025-01-31","2025-03-01","2022-12-12",97,[911],"Patients With Advanced Cancer Receiving Specialized Palliative Care",[888],{"intervention":914,"totalTrials":63,"cells":915},"lung cancer",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":917,"activeCount":67},[],{"trials":919,"activeCount":67},[],{"trials":921,"activeCount":67},[],{"trials":923,"activeCount":67},[],{"trials":925,"activeCount":67},[],{"trials":927,"activeCount":67},[928],{"nctId":929,"briefTitle":930,"status":207,"phases":931,"primaryCompletion":253,"completion":253,"start":932,"enrollment":676,"conditions":933,"interventions":935},"NCT04321499","SHOX2_PTGER4 DNA Methlyation in Lung Cancer",[],"2016-05",[934],"Lungcancer",[914]]